A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants with Smoldering Multiple Myeloma

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-005139-14

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

- To evaluate if daratumumab can effectively decrease M protein in subjects with intermediate or high-risk SMM as assessed by CR rate - To determine if daratumumab reduces the progression/death rate in subjects with intermediate or high-risk SMM


Critère d'inclusion

  • Smoldering multiple myeloma